Due to the late cancellation of the in-person Conference on Retroviruses and Opportunistic Infections (CROI), the 2020 Pre-CROI Community HIV Cure Research Workshop took place via Zoom conference on Saturday, March 7th. We thank all presenters, panelists and participants -…
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.
On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.
Treatment Action Group (TAG) applauds progress in New York towards ending HIV as an epidemic, with record decreases in estimated statewide and citywide HIV incidence in 2018. TAG states that accelerating impact at the community level will be critical to reach the Ending the Epidemic 2020 targets.
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.